IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4495
Positioning
Market Dominance
Services
Business Services
$37M
Robert Leasure
Inotiv, Inc. provides drug discovery and development services to pharmaceutical, chemical, and medical device industries. It operates through two segments, Contract Research Services and Research Products. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = NOTV ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$YALA Yalla Group Ltd | 75 | 89 | 99 | 80 | - | - | 21.3% | 18.6% | 64.5% | 35.7% | 39.5% | 6.5% | 0.0% | 0.0x | $644M | VS | |
$GRVY GRAVITY Co., Ltd. | 75 | 82 | 96 | 71 | - | - | 15.4% | 12.6% | 38.7% | 17.1% | 17.0% | -39.7% | 0.0% | 0.0x | $439M | VS | |
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 73 | 81 | 88 | 94 | 25.0x | 14.1x | 28.1% | 16.8% | 48.1% | 23.8% | 18.5% | 78.6% | 0.0% | 37.0x | $220M | VS | |
$AER AerCap Holdings N.V. | 72 | 60 | 87 | 84 | - | - | 12.4% | 2.9% | 100.0% | 28.2% | 26.2% | 5.5% | 0.8% | 264.0x | $19.4B | VS | |
$HCSG HEALTHCARE SERVICES GROUP INC | 72 | 74 | 88 | 88 | 7.1x | 6.1x | 28.9% | 20.8% | 20.8% | 9.9% | 9.3% | 8.5% | 0.0% | 1.0x | $1.2B | VS | |
$LQDT LIQUIDITY SERVICES INC | 72 | 90 | 88 | 68 | 24.9x | 14.3x | 14.6% | 7.8% | 43.8% | 7.4% | 5.9% | 31.2% | 0.0% | 0.0x | $857M | VS | |
$TRTNpA Triton International Ltd | 71 | 70 | 89 | 70 | - | 1.7x | 18.0% | 4.6% | 97.3% | 52.2% | 32.7% | -3.4% | 0.0% | 271.0x | $8.0B | VS | |
$EDU New Oriental Education & Technology Group Inc. | 71 | 83 | 52 | 77 | - | - | 9.4% | 4.9% | 55.5% | 8.7% | 7.7% | 13.6% | 1.3% | 7.0x | $78.0B | VS | |
$NTES NetEase, Inc. | 71 | 88 | 93 | 68 | - | - | 22.1% | 15.6% | 62.5% | 28.1% | 28.7% | -1.0% | 2.8% | 9.0x | $56.6B | VS | |
$UTI UNIVERSAL TECHNICAL INSTITUTE INC | 70 | 86 | 86 | 72 | 43.2x | 16.0x | 21.4% | 8.0% | 100.0% | 10.0% | 7.5% | 14.1% | 0.0% | 27.0x | $1.8B | VS | |
$NOTV Inotiv, Inc. | 31 | 39 | 45 | 1 | - | 31.8x | -79.7% | -11.8% | 100.0% | -10.0% | -18.4% | 1.6% | 0.0% | 372.0x | $37M | ||
| SECTOR BENCH | - | - | - | - | - | 23.7x | 11.7x | 5.3% | 1.9% | 59.6% | 3.5% | 2.3% | 7.8% | 0.0% | 0.3x | - | REF |
Inotiv, Inc. (NOTV) receives a "Avoid" rating with a composite score of 30.5/100. It ranks #4495 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Robert Leasure
Chief Executive Officer
Labor Force
2,100
39
55
16
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for NOTV
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Average quality profile
High volatility — wider range of outcomes increases timing risk
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Services sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for NOTV.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 39 | 32 | +7ALPHA |
| MOMENTUM | 1 | 0 | +1NEUTRAL |
| VALUATION | 45 | 44 | +1NEUTRAL |
| INVESTMENT | 55 | 90 | -35DRAG |
| STABILITY | 16 | 8 | +8ALPHA |
| SHORT INT | 24 | 9 | +15ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -79.7% (sector 5.3%)
GM 100% vs sector 60%, OM -10% vs sector 4%
Capital turnover N/A
Rev growth 2%, 11yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Inotiv, Inc. with an Avoid rating, assigning a composite score of 30.5/100 and 1 out of 5 stars. Ranked #4495 of 7,333 stocks, NOTV falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
NOTV's quality score of 39/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -79.7% (sector avg: 5.3%), gross margins of 100.0% (sector avg: 59.6%), net margins of -18.4% (sector avg: 2.3%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 45/100, NOTV appears somewhat expensive relative to its fundamentals. Key valuation metrics include an EV/EBITDA of 31.78x, a P/B ratio of 0.08x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
With an investment score of 55/100, NOTV exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 1.6% vs. a sector average of 7.8% and a return on assets of -11.8% (sector: 1.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
Inotiv, Inc. is experiencing notably weak momentum with a score of just 1/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 1.6% year-over-year, while a beta of 2.89 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
Inotiv, Inc. registers a low stability score of 16/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 2.89 and a debt-to-equity ratio of 372.00x (sector avg: 0.3x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
Inotiv, Inc.'s short interest score of 24/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 2.89), elevated leverage (D/E: 372.00x), micro-cap liquidity risk. At $37M (micro-cap), NOTV carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Inotiv, Inc. is a micro-cap company in the Services sector, ranked #0 of 50 in its sector (100th percentile) and #4495 of 7,333 overall (39th percentile). Key comparisons include ROE of -79.7% trailing the 5.3% sector median and operating margins of -10.0% below the 3.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Services peers.
While NOTV currently exhibits a AVOID profile, superior opportunities exist within the SERVICES sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Services Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (1) would have the largest impact on the composite score.
EV/EBITDA 171% ABOVE SECTOR MEDIAN
ROE 1601% BELOW SECTOR MEDIAN
Gross Margin 68% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF DEC 31, 2025 (Q3 FY2025)
We rate Inotiv, Inc. (NOTV) as Avoid with a composite score of 30.5/100 at a current price of $0.27. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in investment (55th percentile) and value (45th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (1th percentile) and stability (16th percentile) tempers our overall conviction. We assign a No Moat rating (18/100), Very High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; balance sheet deleveraging progress; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Inotiv, Inc. holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 30.5/100 places it at rank #4495 in our full 7,333-stock universe. At $37M in market capitalization, Inotiv, Inc. is a small-cap player in the Services space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 2%, though momentum at the 1th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 100% (+40.4pp vs sector) narrow to operating margins of -10% (-13.5pp vs sector) and net margins of -18.4%, yielding a gross-to-net conversion rate of -18%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $0.27, Inotiv, Inc. is trading near fair value based on current fundamentals. Our value factor score of 45/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at EV/EBITDA of 31.8x (at a premium), P/B of 0.1x, P/S of 0.0x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 100% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
The Avoid rating (composite 30.5/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Elevated leverage (372% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
Thin net margins of -18.4% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Weak momentum (1th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
We assign a Very High uncertainty rating to Inotiv, Inc.. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 2.89), significant leverage (372% debt-to-equity), current negative profitability (net margin -18.4%). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 2.89); significant leverage (372% debt-to-equity); current negative profitability (net margin -18.4%); below-average price stability (16th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 16th percentile and quality factor at the 39th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 100% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Inotiv, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-79.7%), elevated leverage (372% D/E), negative profitability, weak asset returns (ROA -11.8%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Inotiv, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Inotiv, Inc. receives a Avoid rating with a composite score of 30.5/100 (rank #4495 of 7,333). Our quantitative framework assigns a No Moat (18/100, trend: stable), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 31/100.
Our analysis does not support a constructive view on Inotiv, Inc. at this time. The combination of limited competitive advantages, very high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Inotiv, Inc. a meaningful economic moat, scoring 18/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 8.8/20.
The strongest moat sources are margin superiority (8.8/20) and growth durability (6.4/20). GM 100% vs sector 60%, OM -10% vs sector 4%. Rev growth 2%, 11yr history. These pillars form the core of Inotiv, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0/20) and reinvestment efficiency (0/20). ROE proxy -79.7% (sector 5.3%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Inotiv, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 100% providing a solid profitability foundation. The margin cascade from 100% gross to -10% operating to -18.4% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 39th percentile.
The margin profile shows gross margins of 100%, operating margins of -10%, net margins of -18.4%. Return metrics include ROE of -79.7% and ROA of -11.8%. Relative to the Services sector, gross margins are 40.4 percentage points above the sector median of 60%, and ROE of -79.7% compares to a sector median of 5.3%.
The balance sheet reflects high leverage with D/E of 372%, which may limit financial flexibility, revenue growth of 2%. The sector median D/E is 0%, putting Inotiv, Inc. at higher leverage than the typical peer. Elevated leverage in combination with the current margin profile warrants close monitoring for any deterioration in debt-servicing capacity.
High beta of 2.89 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
Above 50MA
37.18%
Net New Highs
+51081
Inotiv (NOTV) Q1 2026 earnings call recap: DSA revenue/awards surge, RMS/NHP headwinds, margins, backlog, and debt refinancing.
WEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, is providing public notice regarding its cybersecurity incident that it became aware of on August 8, 2025. As previously described in the Company’s Current Report on Form 8-K filed with the Securities and Ex
Operator: Good day, everyone, and welcome to the Inotiv First Quarter 2026 Earnings Call. [Operator Instructions] Please be advised that today

Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -10.71% and 21.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Inotiv Inc (NOTV) reports mixed results with strong DSA growth offset by RMS declines and increased operating losses.